Literature DB >> 5317012

Serological responses and results of natural infectious challenge of recipients of zonal ultracentrifuged influenza A2-Aichi-2-68 vaccine.

V Knight, R B Couch, R G Douglas, N M Tauraso.   

Abstract

In an epidemic of Hong Kong influenza in a penal institution, acute respiratory illness occurred in 5.6% of 196 inmates given single subcutaneous doses of 332, 535, or 1 265 CCA of zonal centrifuged, inactivated vaccine and in 11.7% of 755 nonvaccinated inmates (P<0.03). The frequency of illness among inmates who received single doses of 54 or 137 CCA of vaccine was not significantly different from that among the nonimmunized inmates (chi(2)=0.93, not significant). The vaccine was prepared with the A2/Aichi/2/68 strain of influenza and administered 7 weeks before the outbreak. Virus shedding was significantly lower in vaccinated inmates with respiratory disease (11.1%) than in nonvaccinated inmates (73.7%, P<0.04).Serological studies showed an increasing mean titre and increasing frequency of 4-fold or greater haemagglutination inhibition and neutralizing antibody responses with increasing dosage of vaccine.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5317012      PMCID: PMC2427987     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  8 in total

1.  EXPERIMENTAL INFECTION OF HUMAN VOLUNTEERS WITH EQUINE INFLUENZA VIRUS.

Authors:  J A KASEL; R H ALFORD; V KNIGHT; G H WADDELL; M M SIGEL
Journal:  Nature       Date:  1965-04-03       Impact factor: 49.962

Review 2.  THE USE OF VOLUNTEERS IN MEDICAL VIROLOGY.

Authors:  V KNIGHT
Journal:  Prog Med Virol       Date:  1964

3.  Amantadine therapy of epidemic influenza a(2) (Hong Kong).

Authors:  V Knight; D Fedson; J Baldini; R G Douglas; R B Couch
Journal:  Infect Immun       Date:  1970-02       Impact factor: 3.441

4.  Purification of large quantities of influenza virus by density gradient centrifugation.

Authors:  C B Reimer; R S Baker; R M Van Frank; T E Newlin; G B Cline; N G Anderson
Journal:  J Virol       Date:  1967-12       Impact factor: 5.103

5.  Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man.

Authors:  R B Couch; R G Douglas; D S Fedson; J A Kasel
Journal:  J Infect Dis       Date:  1971-11       Impact factor: 5.226

6.  Problems of influenza virus vaccine standardization.

Authors:  N M Tauraso; T C O'Brien; E B Seligman
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

7.  Experimental infection in man and horses with influenza A viruses.

Authors:  J A Kasel; R B Couch
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

8.  QUANTITATIVE ASPECTS OF THE RED BLOOD CELL AGGLUTINATION TEST FOR INFLUENZA VIRUS.

Authors:  G L Miller; W M Stanley
Journal:  J Exp Med       Date:  1944-02-01       Impact factor: 14.307

  8 in total
  4 in total

1.  Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.

Authors:  Robert B Couch; Patricia Winokur; Rebecca Brady; Robert Belshe; Wilbur H Chen; Thomas R Cate; Bryndis Sigurdardottir; Amy Hoeper; Irene L Graham; Robert Edelman; Fenhua He; Diane Nino; Jose Capellan; Frederick L Ruben
Journal:  Vaccine       Date:  2007-09-14       Impact factor: 3.641

Review 2.  The influenza pandemic of 2009: lessons and implications.

Authors:  Paul Shapshak; Francesco Chiappelli; Charurut Somboonwit; John Sinnott
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

3.  High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults.

Authors:  W A Keitel; R B Couch; T R Cate; K R Hess; B Baxter; J M Quarles; R L Atmar; H R Six
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

4.  Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.

Authors:  Robert B Couch; William K Decker; Budi Utama; Robert L Atmar; Diane Niño; Jing Qi Feng; Matthew M Halpert; Gillian M Air
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.